Chizuko Hashimoto

1.8k total citations
46 papers, 1.0k citations indexed

About

Chizuko Hashimoto is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Chizuko Hashimoto has authored 46 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pathology and Forensic Medicine, 22 papers in Oncology and 19 papers in Neurology. Recurrent topics in Chizuko Hashimoto's work include Lymphoma Diagnosis and Treatment (35 papers), CNS Lymphoma Diagnosis and Treatment (19 papers) and Viral-associated cancers and disorders (15 papers). Chizuko Hashimoto is often cited by papers focused on Lymphoma Diagnosis and Treatment (35 papers), CNS Lymphoma Diagnosis and Treatment (19 papers) and Viral-associated cancers and disorders (15 papers). Chizuko Hashimoto collaborates with scholars based in Japan, United States and India. Chizuko Hashimoto's co-authors include Rie Hyo, Naoto Tomita, Yoshiaki Ishigatsubo, Ritsuro Suzuki, Hiroshi Kimura, Kazuo Oshimi, Koji Izutsu, Junji Suzumiya, Shigeo Nakamura and Fumihiro Ishida and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Chizuko Hashimoto

45 papers receiving 1.0k citations

Peers

Chizuko Hashimoto
Rie Hyo Japan
Biljana Mihaljević Serbia
Sophie Lefort France
Reem Karmali United States
Olivier Fitoussi France
Alina S. Gerrie Canada
Lorella Orsucci Italy
Jun‐ichi Tamaru Japan
M. Jesús Nambo Mexico
Alessia Bari Italy
Rie Hyo Japan
Chizuko Hashimoto
Citations per year, relative to Chizuko Hashimoto Chizuko Hashimoto (= 1×) peers Rie Hyo

Countries citing papers authored by Chizuko Hashimoto

Since Specialization
Citations

This map shows the geographic impact of Chizuko Hashimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chizuko Hashimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chizuko Hashimoto more than expected).

Fields of papers citing papers by Chizuko Hashimoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chizuko Hashimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chizuko Hashimoto. The network helps show where Chizuko Hashimoto may publish in the future.

Co-authorship network of co-authors of Chizuko Hashimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Chizuko Hashimoto. A scholar is included among the top collaborators of Chizuko Hashimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chizuko Hashimoto. Chizuko Hashimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tachibana, Takayoshi, Takaaki Takeda, Yotaro Tamai, et al.. (2025). Preconditioning intervention prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia. Experimental Hematology. 144. 104746–104746. 1 indexed citations
2.
Miyazaki, Takuya, Hiroyuki Takahashi, Takaaki Takeda, et al.. (2025). Delayed Methotrexate Elimination Following High-dose Methotrexate Prophylaxis in High-risk Diffuse Large B-cell Lymphoma. Internal Medicine. 64(18). 2716–2722. 2 indexed citations
3.
Miyazaki, Takuya, Hiroyuki Takahashi, Yusuke Saigusa, et al.. (2024). Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse. International Journal of Hematology. 119(2). 164–172. 2 indexed citations
4.
Takahashi, Hiroyuki, Rika Sakai, Yoshimi Ishii, et al.. (2020). Comparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma: A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study. Indian Journal of Hematology and Blood Transfusion. 37(1). 60–66. 4 indexed citations
5.
Yamazaki, Etsuko, Yoshimi Ishii, Wataru Yamamoto, et al.. (2017). Body mass index is a prognostic factor in adult patients with acute myeloid leukemia. International Journal of Hematology. 105(5). 623–630. 10 indexed citations
6.
Tomita, Naoto, Taisei Suzuki, Hiroyuki Takahashi, et al.. (2015). R-CHOP therapy alone for limited-stage follicular lymphoma. Leukemia Research. 39(6). 582–585. 3 indexed citations
7.
Tomita, Naoto, Shin Fujisawa, Chizuko Hashimoto, et al.. (2014). Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma. Annals of Hematology. 94(3). 431–436. 18 indexed citations
8.
9.
Nakajima, Yuki, Naoto Tomita, Reina Watanabe, et al.. (2014). Analysis of outcomes in patients with supra-diaphragmatic vs infra-diaphragmatic diffuse large B cell lymphoma treated with R-CHOP therapy. Leukemia Research. 39(2). 198–203. 9 indexed citations
10.
Takasaki, Hirotaka, Wataru Yamamoto, Yoshimi Ishii, et al.. (2014). Post-treatment PET–CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass. Indian Journal of Hematology and Blood Transfusion. 31(3). 346–351. 7 indexed citations
11.
Yamamoto, Eri, Naoto Tomita, Seiji Sakata, et al.. (2013). MIB‐1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy. Cancer Science. 104(12). 1670–1674. 12 indexed citations
12.
Watanabe, Reina, Naoto Tomita, Satoshi Koyama, et al.. (2013). Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Leukemia Research. 37(10). 1208–1212. 15 indexed citations
13.
Ito, Yoshinori, Hiroshi Kimura, Chizuko Hashimoto, et al.. (2012). Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type. Clinical Cancer Research. 18(15). 4183–4190. 77 indexed citations
14.
Tomita, Naoto, Rika Sakai, Shin Fujisawa, et al.. (2012). SIL index, comprising stage, soluble interleukin‐2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B‐cell lymphoma. Cancer Science. 103(8). 1518–1523. 18 indexed citations
15.
Takahashi, Hiroyuki, Naoto Tomita, Masahiro Yokoyama, et al.. (2011). Prognostic impact of extranodal involvement in diffuse large B‐cell lymphoma in the rituximab era. Cancer. 118(17). 4166–4172. 73 indexed citations
16.
Yamamoto, Wataru, Naoto Tomita, Reina Watanabe, et al.. (2010). Central nervous system involvement in diffuse large B‐cell lymphoma. European Journal Of Haematology. 85(1). 6–10. 65 indexed citations
17.
Tomita, Naoto, Kengo Takeuchi, Rie Hyo, et al.. (2009). Diffuse Large B Cell Lymphoma without Immunoglobulin Light Chain Restriction by Flow Cytometry. Acta Haematologica. 121(4). 196–201. 17 indexed citations
18.
Hyo, Rie, Naoto Tomita, Kengo Takeuchi, et al.. (2009). The therapeutic effect of rituximab on CD5‐positive and CD5‐negative diffuse large B‐cell lymphoma. Hematological Oncology. 28(1). 27–32. 28 indexed citations
19.
Koharazawa, Hideyuki, Heiwa Kanamori, Rika Sakai, et al.. (2008). Long-term outcome of L86 and L97 protocols for adult acute lymphoblastic leukemia. Leukemia & lymphoma. 49(11). 2133–2140. 3 indexed citations
20.
Tomita, Naoto, Fumio Kodama, S Motomura, et al.. (2007). Adjuvant radiotherapy to an initial bulky mass in diffuse large B‐cell lymphoma: lack of survival benefit. International Journal of Laboratory Hematology. 30(1). 53–57. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rie Hyo Breakdown of academic impact, for papers by Biljana Mihaljević Breakdown of academic impact, for papers by Sophie Lefort Breakdown of academic impact, for papers by Reem Karmali Breakdown of academic impact, for papers by Olivier Fitoussi Breakdown of academic impact, for papers by Alina S. Gerrie Breakdown of academic impact, for papers by Lorella Orsucci Breakdown of academic impact, for papers by Jun‐ichi Tamaru Breakdown of academic impact, for papers by M. Jesús Nambo Breakdown of academic impact, for papers by Alessia Bari
Rankless by CCL
2026